PARP1 and pachyonychia congenita: Combined inhibition of AR and PARP by olaparib plus enzalutamide decreased the proliferation of PC cells in xenograft PC model mice after 1 week of treatment, suggesting that the combination may synergistically inhibit tumor growth (36).